Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy

Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02030548

Enrollment

144

Registered

2014-01-08

Start date

2013-11-30

Completion date

2016-11-30

Last updated

2019-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

CABG, dual antiplatelet therapy, aspirin, clopidogrel, prasugrel, ticagrelor

Brief summary

The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel, Ticagrelor)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

consecutive patients undergoing acute CABG with or without valve replacement within 7 days after last intake of dual antiplatelet therapy

Exclusion criteria

concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest

Design outcomes

Primary

Measure	Time frame
calculated blood loss	until postoperative day 5

Secondary

Measure	Time frame
mortality	from index surgery until one year after index surgery

Countries

Austria

Outcome results